Heidi, the clinical-note AI startup, has secured a $140 million Series C round, doubling its valuation to $1.26 billion in less than a year. The funding will support its global expansion and AI agent development.
TL;DR
- Heidi raises $140M in Series C, valuing the company at $1.26B.
- The funding will support global expansion and AI agent development.
- Heidi's software is used in over 20 million patient interactions across 190 countries.
What happened
Heidi, the clinical-note AI startup, has raised $140 million in a Series C round, led by Blackbird, with participation from existing investors Phoenix Court, Point72 Private Investments, and Headline. This round values the company at $1.26 billion, nearly double its $703 million valuation from less than a year ago.
In addition to the Series C, Heidi also secured a separate $240 million growth investment led by General Catalyst's Customer Value Fund. This brings the total new funding to $340 million.
Heidi's software records consultations and produces clinical notes, aiming to improve clinician efficiency. The company reports that its annual recurring revenue reached $50 million in April, up from $1 million two years ago.
Why it matters
The funding will enable Heidi to expand its AI agent development, allowing for task completion under clinical supervision. This could significantly impact the healthcare industry by increasing clinician efficiency and patient interactions.
Heidi's global reach, with operations in 190 countries and 110 languages, positions it as a major player in the clinical-note AI market. The company claims to be the world's largest scribe by volume, handling 2.8 million notes weekly.
The investment underscores the growing importance of AI in healthcare and the potential for startups to disrupt traditional markets. For investors, this represents a significant opportunity in the burgeoning healthcare AI sector.
Key facts
- Heidi raised $140 million in a Series C round, valuing the company at $1.26 billion.
- The Series C was led by Blackbird, with participation from Phoenix Court, Point72 Private Investments, and Headline.
- A separate $240 million growth investment was led by General Catalyst's Customer Value Fund.
- Heidi's valuation has nearly doubled in less than a year, up from $703 million.
- The company's annual recurring revenue reached $50 million in April, up from $1 million two years ago.
- Heidi's software is used in over 20 million patient interactions across 190 countries and 110 languages.
- The company handles 2.8 million notes weekly, claiming to be the world's largest scribe by volume.
- Heidi was founded in 2021 as Oscar and launched its software in February 2024.
Context
Heidi's success highlights the increasing role of AI in healthcare, particularly in improving clinician efficiency and patient outcomes. The company's rapid growth and significant funding reflect the market's demand for innovative solutions in clinical documentation.
The healthcare AI sector is attracting substantial investment, with startups like Heidi leading the charge. This investment round positions Heidi as a key player in the global market, with significant potential for further growth and impact.
As AI continues to transform the healthcare industry, companies like Heidi are at the forefront of this change. Their success not only benefits investors but also has the potential to revolutionize clinical practices worldwide.
